Table 6 Results of GSVA for risk groups.

REACTOME CRISTAE FORMATION

1.30E − 15

3.81E − 12

REACTOME INHIBITION OF REPLICATION INITIATION OF DAMAGED DNA BY RB1 E2F1

2.72E − 13

4.00E − 10

REACTOME MASTL FACILITATES MITOTIC PROGRESSION

1.56E − 11

7.63E − 09

REACTOME ANTIGEN PRESENTATION FOLDING ASSEMBLY AND PEPTIDE LOADING OF CLASS I MHC

2.05E − 12

2.02E − 09

REACTOME FORMATION OF APOPTOSOME

1.18E − 08

4.09E − 07

REACTOME CYTOCHROME C MEDIATED APOPTOTIC RESPONSE

3.78E − 09

2.37E − 07

REACTOME AUF1 HNRNP D0 BINDS AND DESTABILIZES MRNA

4.05E − 11

1.32E − 08

REACTOME CITRIC ACID CYCLE TCA CYCLE

1.10E − 09

9.99E − 08

KEGG MEDICUS REFERENCE COPII VESICLE FORMATION

1.88E − 08

5.58E − 07

WP TCA CYCLE AKA KREBS OR CITRIC ACID CYCLE

7.10E − 09

2.97E − 07

BIOCARTA EIF PATHWAY

1.24E − 09

9.99E − 08

WP INHIBITION OF EXOSOME BIOGENESIS AND SECRETION BY MANUMYCIN A IN CRPC CELLS

1.09E − 08

3.91E − 07

WP TGF SMAD SIGNALING PATHWAY

7.72E − 09

3.01E − 07

KEGG MEDICUS REFERENCE ISOLEUCINE DEGRADATION

6.43E − 07

7.48E − 06

KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO 26 S PROTEASOME MEDIATED PROTEIN DEGRADATION

6.84E − 09

2.97E − 07

KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT SOD1 TO 26 S PROTEASOME MEDIATED PROTEIN DEGRADATION

4.74E − 09

2.63E − 07

KEGG MEDICUS VARIANT SCRAPIE CONFORMATION PRPSC TO 26 S PROTEASOME MEDIATED PROTEIN DEGRADATION

8.90E − 09

3.36E − 07

WP PROTEASOME DEGRADATION

3.25E − 11

1.19E − 08

WP TCA CYCLE AND DEFICIENCY OF PYRUVATE DEHYDROGENASE COMPLEX PDHC

2.38E − 07

3.55E − 06

REACTOME PLATELET SENSITIZATION BY LDL

7.71E − 12

4.83E − 09